Sarepta (SRPT) Soars 15% on Bullish Rating
In a market note, Mizuho Securities raised its rating for Sarepta Therapeutics Inc.
Sarepta Therapeutics Inc. (SRPT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 80,000,000 | $64,000,000 | 1.08% | ||
| 2. | 68,680,000 | $60,404,060 | 0.1% | ||
| 3. | 67,000,000 | $58,938,453 | +55% | 0.07% | |
| 4. | Renaissance Technologies Jim Simons | 2,650,178 | $51,068,930 | +325% | 0.07% |
| 5. | D E Shaw D. E. Shaw | 2,007,025 | $38,675,372 | -56% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $134.66 | 5,648 | $760,559.68 | 284,034 | 2024-08-16 | Filing | |
| $134.06 | 18,284 | $2,451,153.04 | 278,386 | 2024-08-16 | Filing | |
| $133.07 | 13,106 | $1,744,015.42 | 260,102 | 2024-08-16 | Filing | |
| $78.81 | 40,000 | $3,152,400.00 | 140,000 | 2023-11-03 | Filing | |
| $78.81 | 10,000 | $788,100.00 | 10,000 | 2023-11-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.64 | 2,491 | $248,203.24 | 27,812 | 2025-03-12 | Filing | |
| $124.84 | 10,500 | $1,310,820.00 | 22,840 | 2024-12-12 | Filing | |
| $125.55 | 1,636 | $205,399.80 | 5,880 | 2024-12-05 | Filing | |
| $137.36 | 5,985 | $822,099.60 | 33,946 | 2024-08-30 | Filing | |
| $164.52 | 2,549 | $419,361.48 | 17,129 | 2024-06-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,199,845 | $254,361,023 | 0% | |
| 2. | 10,817,446 | $208,452,185 | 0% | |
| 3. | 5,304,907 | $102,225,558 | 0% | |
| 4. | 2,685,945 | $50,588,160 | 0.49% | |
| 5. | 2,137,764 | $41,194,712 | 0.06% |
News See All
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to Sarepta's Third Quarter 2025 Financial Results Conference Call. As a reminder, today's program is being recorded.
Sarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial Results
Sarepta Therapeutics extended its winning streak to a 5th consecutive day on Thursday, surging 15.68 percent to close at $22.35 apiece as investors repositioned portfolios ahead of the upcoming preliminary...
Sarepta Therapeutics (SRPT) Fell Despite Reporting Good Results
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Jim Cramer Talked About These 15 Stocks
“Even though today's Producer Price Index number was way too high, wage inflation's the real battleground, and I think the battle is being won by the machines...
Sarepta Therapeutics, Inc. (SRPT): "You Don't Court Homicide," Says Jim Cramer
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has had a controversial time on the stock market in July.
11 Stocks That Jim Cramer Recently Talked About
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed why fighter and bomber pilots lead to high defense spending.
BMO Capital Cuts Sarepta Therapeutic (SRPT) PT to $25 from $50
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most undervalued stocks to buy and hold for 3 years.
10 Most Undervalued Stocks to Buy and Hold for 3 Years
On July 17, Lori Calvasina, RBC Capital Markets head of US equity strategy, joined 'Closing Bell' on CNBC to discuss whether the market is fully valued at present levels.
Sarepta Therapeutics (SRPT): "They Should Be Prosecuted," Says Jim Cramer
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a biotechnology company that focuses on gene-based therapies.